Multifunctional CD4 +T cells in patients with American cutaneous leishmaniasis

Clinical and Experimental Immunology

Volumn 167, Issue 3, 2012, Pages 505-513

  Macedo, A B B ^a,d   Sanchez Arcila J C ^a   Schubach, A O ^c   Mendonca S C F ^a   Marins Dos Santos, A ^b   De Fatima Madeira, M ^c   Gagini, T ^a   Pimentel, M I F ^c   De Luca, P M ^a  

^a Laboratório de Imunoparasitologia   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c Funda??o Oswaldo Cruz   (Brazil)

^d CENTRE D IMMUNOLOGIE DE MARSEILLE LUMINY   (France)

Author keywords

Human American cutaneous leishmaniasis; Leishmania amazonensis; Leishmania braziliensis; Multifunctional T cells

Indexed keywords

GAMMA INTERFERON; PARASITE ANTIGEN;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CELL STIMULATION; CLINICAL ARTICLE; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOPATHOGENESIS; LEISHMANIA; LEISHMANIA BRAZILIENSIS; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROMASTIGOTE; SKIN LEISHMANIASIS; SUSCEPTIBILITY WEIGHTED IMAGING; TH1 CELL;

ADULT; ANTIGENS, PROTOZOAN; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; FEMALE; FLOW CYTOMETRY; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-2; LEISHMANIA BRAZILIENSIS; LEISHMANIA MEXICANA; LEISHMANIASIS, CUTANEOUS; MALE; MIDDLE AGED; SPECIES SPECIFICITY; TH1 CELLS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84856377995     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2011.04536.x     Document Type: Article

References (63)

1. World Health Organization (WHO). Leishmaniasis. Available at: (accessed 27 June 2011).
2. Schwartz E, Hatz C, Blum J. New world cutaneous leishmaniasis in travellers. Lancet Infect Dis 2006; 6:342-9.
3. Grimaldi G Jr, Tesh RB. Leishmaniases of the New World: current concepts and implications for future research. Clin Microbiol Rev 1993; 6:230-50.
4. de Oliveira-Neto MP, Mattos MS, Perez MA etal. American tegumentary leishmaniasis (ATL) in Rio de Janeiro State, Brazil: main clinical and epidemiologic characteristics. Int J Dermatol 2000; 39:506-14.
5. Guerra JA, Prestes SR, Silveira H etal. Mucosal leishmaniasis caused by Leishmania (Viannia) braziliensis and Leishmania (Viannia) guyanensis in the Brazilian Amazon. PLoS Negl Trop Dis 2011; 5:e980.
6. Bittencourt A, Silva N, Straatmann A etal. Post-kala-azar dermal leishmaniasis associated with AIDS. Braz J Infect Dis 2003; 7:229-33.
7. Costa JM, Marsden PD, Llanos-Cuentas EA etal. Disseminated cutaneous leishmaniasis in a field clinic in Bahia, Brazil: a report of eight cases. J Trop Med Hyg 1986; 89:319-23.
8. Turetz ML, Machado PR, Ko AI etal. Disseminated leishmaniasis: a new and emerging form of leishmaniasis observed in northeastern Brazil. Braz J Infect Dis 2002; 186:1829-34.
9. Almeida RP, Barral-Netto M, De Jesus AM etal. Biological behavior of Leishmania amazonensis isolated from humans with cutaneous, mucosal, or visceral leishmaniasis in BALB/C mice. Am J Trop Med Hyg 1996; 54:178-84.
10. Petersen EA, Neva FA, Barral A etal. Monocyte suppression of antigen-specific lymphocyte responses in diffuse cutaneous leishmaniasis patients from the Dominican Republic. J Immunol 1984; 132:2603-6.
11. Lainson R, Bray RS. Studies on the immunology and serology of leishmaniasis. II. Cross-immunity experiments among different forms of American cutaneous leishmaniasis in monkeys. Trans R Soc Trop Med Hyg 1966; 60:526-32.
12. Lainson R, Shaw JJ. Studies on the immunology and serology of leishmaniasis. 3. On the cross-immunity between Panamanian cutaneous leishmaniasis and Leishmania mexicana infection in man. Trans R Soc Trop Med Hyg 1966; 60:533-5.
13. Lainson R, Shaw JJ. Leishmaniasis in Brazil: XII. Observations on cross-immunity in monkeys and man infected with Leishmania mexicana mexicana, L. m. amazonensis, L. braziliensis braziliensis, L. b. guyanensis and L. b. panamensis. J Trop Med Hyg 1977; 80:29-35.
14. Porrozzi R, Teva A, Amaral VF etal. Cross-immunity experiments between different species or strains of Leishmania in rhesus macaques (Macaca mulatta). Am J Trop Med Hyg 2000; 71:297-305.
15. Bacellar O, Lessa H, Schriefer A etal. Up-regulation of Th1-type responses in mucosal leishmaniasis patients. Infect Immun 2002; 70:6734-40.
16. Faria DR, Gollob KJ, Barbosa J Jr etal. Decreased in situ expression of interleukin-10 receptor is correlated with the exacerbated inflammatory and cytotoxic responses observed in mucosal leishmaniasis. Infect Immun 2005; 73:7853-9.
17. Gaze ST, Dutra WO, Lessa M etal. Mucosal leishmaniasis patients display an activated inflammatory T-cell phenotype associated with a nonbalanced monocyte population. Scand J Immunol 2006; 63:70-8.
18. Silveira FT, Lainson R, De Castro Gomes CM etal. Immunopathogenic competences of Leishmania (V.) braziliensis and L. (L.) amazonensis in American cutaneous leishmaniasis. Parasite Immunol 2009; 31:423-31.
19. Glimcher LH, Murphy KM. Lineage commitment in the immune system: the T helper lymphocyte grows up. Genes Dev 2000; 14:1693-711.
20. Iezzi G, Karjalainen K, Lanzavecchia A. The duration of antigenic stimulation determines the fate of naive and effector T cells. Immunity 1998; 8:89-95.
21. Maldonado-Lopez R, Moser M. Dendritic cell subsets and the regulation of Th1/Th2 responses. Semin Immunol 2001; 13:275-82.
22. O'Garra A. Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity 1998; 8:275-83.
23. Wu CY, Kirman JR, Rotte MJ etal. Distinct lineages of T(H)1 cells have differential capacities for memory cell generation in vivo. Nat Immunol 2002; 3:852-8.
24. Foulds KE, Rotte MJ, Paley MA etal. IFN-gamma mediates the death of Th1 cells in a paracrine manner. J Immunol 2008; 180:842-9.
25. Younes SA, Yassine-Diab B, Dumont AR etal. HIV-1 viremia prevents the establishment of interleukin 2-producing HIV-specific memory CD4+ T cells endowed with proliferative capacity. J Exp Med 2003; 198:1909-22.
26. Harari A, Petitpierre S, Vallelian F etal. Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy. Blood 2004; 103:966-72.
27. Boaz MJ, Waters A, Murad S etal. Presence of HIV-1 Gag-specific IFN-γ+IL-2+ and CD28+IL-2+ CD4 T cell responses is associated with nonprogression in HIV-1 infection. J Immunol 2002; 169:6376-85.
28. Duvall MG, Jaye A, Dong T etal. Maintenance of HIV-specific CD4+ T cell help distinguishes HIV-2 from HIV-1 infection. J Immunol 2006; 176:6973-81.
29. Semmo N, Day CL, Ward SM etal. Preferential loss of IL-2-secreting CD4+ T helper cells in chronic HCV infection. Hepatology 2005; 41:1019-28.
30. Millington KA, Innes JA, Hackforth S etal. Dynamic relationship between IFN-γ and IL-2 profile of Mycobacterium tuberculosis specific T cells and antigen load. J Immunol 2007; 178:5217-26.
31. Darrah PA, Patel DT, De Luca PM etal. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007; 13:843-50.
32. Lindenstrøm T, Agger EM, Korsholm KS etal. Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells. J Immunol 2009; 182:8047-55.
33. Derrick SC, Yabe IM, Yang A etal. Vaccine-induced anti-tuberculosis protective immunity in mice correlates with the magnitude and quality of multifunctional CD4 T cells. Vaccine 2011; 29:2902-9.
34. Draper SJ, Biswas S, Spencer AJ etal. Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines. J Immunol 2010; 185:7583-95.
35. Yu H, Karunakaran KP, Kelly I etal. Immunization with live and dead Chlamydia muridarum induces different levels of protective immunity in a murine genital tract model: correlation with MHC class II peptide presentation and multifunctional Th1 cells. J Immunol 2011; 186:3615-21.
36. Silveira FT, Lainson R, Corbett CE. Clinical and immunopathological spectrum of American cutaneous leishmaniasis with special reference to the disease in Amazonian Brazil: a review. Mem Inst Oswaldo Cruz 2004; 99:239-51.
37. Mendonça SC, Coutinho SG, Amendoeira RR etal. Human American cutaneous leishmaniasis (Leishmania b. braziliensis) in Brazil: lymphoproliferative responses and influence of therapy. Clin Exp Immunol 1986; 64:269-76.
38. Cupolillo E, Grimaldi G, Jr, Momen H. A general classification of new world leishmania using numerical zymotaxonomy. Am J Trop Med Hyg 1994; 50:296-311.
39. Reithinger R, Dujardin JC, Louzir H etal. Cutaneous leishmaniasis. Lancet Infect Dis 2007; 7:581-96.
40. Pinheiro RO, Pinto EF, Benedito AB etal. The T-cell anergy induced by Leishmania amazonensis antigens is related with defective antigen presentation and apoptosis. An Acad Bras Cienc 2004; 76:519-27.
41. Afonso LC, Scott P. Immune responses associated with susceptibilityof C57BL/10 mice to Leishmania amazonensis. Infect Immun 1993; 61:2952-59.
42. + T cells in pathogenesis associated with Leishmania amazonensis infection. J Immunol 1997; 158:5374-83.
43. Jones DE, Buxbaum LU, Scott P. IL-4-independent inhibition of IL-12 responsiveness during Leishmania amazonensis infection. J Immunol 2000; 165:364-72.
44. Lemos de Souza V, Ascenção JS, Correia TMS etal. Different Leishmania species determine distinct profiles of immune and histopathological responses in CBA mice. Microbes Infect 2000; 2:1807-15.
45. Ji J, Sun J, Hai J etal. Analysis of T helper cell responses during infection with Leishmania amazonensis. Am J Trop Med Hyg 2002; 66:338-45.
46. Jones DE, Ackermann MR, Wille U etal. Early enhanced Th1 response after Leishmania amazonensis infection of C57BL/6 interleukin-10-deficient mice does not lead to resolution of infection. Infect Immun 2002; 70:2151-8.
47. Ji J, Sun J, Soong L. Impaired expression of inflammatory cytokines and chemokines at early stages of infection with Leishmania amazonensis. Infect Immun 2003; 71:4278-88.
48. Telino E, De Luca PM, Matos DCS etal. In vitro responses of human peripheral blood mononuclear cells to whole-cell, particulate and soluble extracts of Leishmania promastigotes. Clin Exp Immunol 2005; 143:338-44.
49. Silveira FT, Blackwell JM, Ishikawa EA etal. T cell responses to crude and defined leishmanial antigens in patients from the Lower Amazon region of Brazil infected with different species of Leishmania of the subgenera Leishmania and Viannia. Parasite Immunol 1998; 20:19-26.
50. Azeredo-Coutinho RB, Matos DC, Armôa GG etal. Contrasting human cytokine responses to promastigote whole-cell extract and the Leishmania analogue receptor for activated C kinase antigen of L. amazonensis in natural infection versus immunization. Clin Exp Immunol 2008; 153:369-75.
51. Coêlho ZC, Teixeira MJ, Mota EF etal. In vitro initial immune response against Leishmania amazonensis infection is characterized by an increased production of IL-10 and IL-13. Braz J Infect Dis 2010; 14:476-82.
52. Pereira RM, Teixeira KL, Barreto-de-Souza V etal. Novel role for the double-stranded RNA-activated protein kinase PKR: modulation of macrophage infection by the protozoan parasite Leishmania. FASEB J 2010; 24:617-26.
53. Yang Z, Mosser DM, Zhang X. Activation of the MAPK, ERK, following Leishmania amazonensis infection of macrophages. J Immunol 2007; 178:1077-85.
54. Veras PS, Welby-Borges M, de Santana CD etal. Leishmania amazonensis: participation of regulatory T and B cells in the in vitro priming (PIV) of CBA/J spleen cells susceptible response. Exp Parasitol 2006; 113:201-5.
55. Hernández-Ruiz J, Salaiza-Suazo N, Carrada G etal. CD8 cells of patients with diffuse cutaneous leishmaniasis display functional exhaustion: the latter is reversed, in vitro, by TLR2 agonists. PLoS Negl Trop Dis 2010; 4:e871.
56. Kenney RT, Sacks DL, Sypek JP etal. Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis. J Immunol 1999; 163:4481-8.
57. Pinheiro RO, Pinto EF, Lopes JRB etal. TGF-β-associated enhanced susceptibility to leishmaniasis following intramuscular vaccination of mice with Leishmania amazonensis antigens. Microbiol Infect 2005; 7:1317-23.
58. Marzochi KB, Marzochi MA, Silva AF etal. Phase 1 study of an inactivated vaccine against American tegumentary leishmaniasis in normal volunteers in Brazil. Mem Inst Oswaldo Cruz 1998; 93:205-12.
59. Velez ID, Agudelo S, Arbelaez P etal. Safety and immunogenicity of a killed Leishmania (L.) amazonensis vaccine against cutaneous leishmaniasis in Colombia: a randomized controlled trial. Trans R Soc Trop Med Hyg 2000; 94:698-703.
60. De Luca PM, Mayrink W, Pinto JA etal. A randomized double blind placebo-controlled trial to evaluate the immunogenicity of a candidate vaccine against American tegumentary leishmaniasis. Acta Trop 2001; 80:251-60.
61. Velez ID, Gilchrist K, Arbelaez MP etal. Failure of a killed Leishmania amazonensis vaccine against American cutaneous leishmaniasis in Colombia. Trans R Soc Trop Med Hyg 2005; 99:593-8.
62. Toledo VPCP, Mayrink W, Gollob KJ etal. Immunochemotherapy in American cutaneous leishmaniasis: immunological aspects before and after treatment. Mem Inst Oswaldo Cruz 2001; 96:89-98.
63. Convit J, Ulrich M, Zerpa O etal. Immunotherapy of American cutaneous leishmaniasis in Venezuela during the period 1990-99. Trans R Soc Trop Med Hyg 2003; 97:469-72.